Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
暂无分享,去创建一个
Tobias Nordström | Henrik Grönberg | H. Grönberg | J. Adolfsson | M. Aly | M. Clements | T. Nordström | Jan Adolfsson | Markus Aly | C. Weibull | Mark S Clements | Caroline E Weibull
[1] S. Bojesen,et al. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Supramaniam,et al. Prostate cancer and prostate‐specific antigen testing in New South Wales , 2008, The Medical journal of Australia.
[3] E. Feuer,et al. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey , 2007, Cancer.
[4] L. Holmberg,et al. The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.
[5] B. G. Blijenberg,et al. Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.
[6] Thomas Wiegel,et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.
[7] P. Carroll,et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .
[8] A. Ruffion,et al. Consommation du dosage de l’antigène spécifique de la prostate (PSA) en France chez les hommes sans cancer de la prostate déclaré (2008-2010) , 2012 .
[9] W. Catalona,et al. Platinum Priority – Collaborative Review – Prostate Cancer Baseline Prostate-specific Antigen Testing at a Young Age Hemodilution and Psa Concentration among Men with Prostate Psa Values Using Sequence Variants Associated with Psa Levels. Sci Goteborg Randomised Population-based Prostate-cancer Scre , 2022 .
[10] S. Duffy,et al. Uptake of prostate‐specific antigen testing for early prostate cancer detection in Sweden , 2011, International journal of cancer.
[11] Philip D. Harvey,et al. A systematic review of the diagnostic accuracy of prostate specific antigen , 2009, BMC urology.
[12] H. Comber,et al. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines , 2010, Irish journal of medical science.
[13] A. Jha,et al. Trends in prostate-specific antigen testing from 1995 through 2004. , 2007, Archives of internal medicine.
[14] P. Scardino,et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study , 2010, BMJ : British Medical Journal.
[15] S. Moss,et al. Rates of prostate‐specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross‐sectional study , 2004, BJU international.
[16] Christina Bougatsos,et al. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.
[17] Hans Garmo,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.
[18] J. Oesterling,et al. Predictive properties of serum-prostate-specific antigen testing in a community-based setting. , 1996, Archives of internal medicine.
[19] J. Gohagan,et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.
[20] T. Stamey,et al. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .
[21] F. Hamdy,et al. Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities , 2011, BJU international.
[22] Y. Taylor,et al. Trends in Prostate-Specific Antigen Test Use, 2000–2005 , 2011, Public health reports.
[23] J. Oesterling,et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.
[24] J. Anderson,et al. Age-specific reference ranges for serum prostate-specific antigen. , 1995, Urology.
[25] Jim C Hu,et al. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. , 2012, JAMA.
[26] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[27] Ian M Thompson,et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.